bioRxiv Science⌕ Search

Biology subjects

Burnard, D.

Publications and source records attributed to Burnard, D..

2 recordsLinked to original sources

Metagenomic resolution of spotted-fever group Rickettsia tasmanensis and novel DNA viruses in Australian wildlife ticks, with spatial modelling of Rickettsia exposure zones.

Australia's spotted fever group (SFG) rickettsiae cause significant illness, yet microbial diversity in wildlife ticks remains incompletely understood. Metagenomic sequencing of nine tick pools representing three Ixodidae species, Ixodes tasmani, I. holocyclus, and Haemaphysalis bancrofti, from Australian wildlife revealed a genome of a novel SFG Rickettsia species from I. tasmani ticks collected from koalas in New South Wales. Phylogenomic analysis confirmed this as a distinct species closely related to Rickettsia tasmaniensis fragments previously reported from Tasmanian devils. Additionally, we discovered four novel DNA Anellovirus species forming a new genus 'Sintorquevirus' and one Circovirus from likely vertebrate blood meals, revealing wildlife viral diversity. Species distribution modelling of I. tasmani for assessing Rickettsia risk revealed suitable habitat along Australia's eastern coastlines, with overlap between vector distribution, marsupial hosts, and population centres. This identified potential Candidatus R. tasmanensis exposure zones in coastal regions where positive samples originated, highlighting areas for surveillance.

microbiology↗

Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a novel siderophore cephalosporin

Cefiderocol is a novel cephalosporin designed to treat multidrug resistant Gram-negative infections. By forming a chelated complex with ferric iron, cefiderocol is transported into the periplasmic space via bacterial iron transport systems and primarily binds to penicillin-binding protein 3 (PBP3) to inhibit peptidoglycan synthesis. This mode of action results in cefiderocol having greater in vitro activity against many Gram-negative bacilli than currently used carbapenems, {beta}-lactam/{beta}-lactamase inhibitor combinations, and cephalosporins. Thus, we investigated the in vitro activity of cefiderocol (S-649266) against a total of 271 clinical isolates of Burkholderia pseudomallei from Australia. The collection was comprised of primary isolates (92.3%) and subsequent isolates (7.7%). Minimum inhibitory concentrations (MIC) of cefiderocol ranged from [≤]0.03 to 32 mg/L, where the MIC90 was 1 mg/L and 16 mg/L for primary and subsequent isolates, respectively. Based upon non-species specific (Gram-negative bacilli) clinical breakpoints for cefiderocol (MIC [≤] 4 mg/L), twelve isolates (4.4%) would be classified as non-susceptible. Further testing for co-resistance to meropenem, ceftazidime, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate and doxycycline was performed on a subset of isolates with elevated cefiderocol MICs ([≥]2 mg/L, 4.8%) and 84.6% of these isolates exhibited resistance to at least one of these antimicrobials. Cefiderocol was found to be highly active in vitro against B. pseudomallei primary clinical isolates. This novel compound shows great potential for the treatment of melioidosis in endemic countries and should be explored further.

microbiology↗